サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1402418

人工多能性幹細胞 (iPSC)：世界市場

Induced Pluripotent Stem Cells: Global Markets
出版日: | 発行: BCC Research | ページ情報: 英文 121 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
人工多能性幹細胞 (iPSC)：世界市場
出版日: 2024年01月04日
発行: BCC Research
ページ情報: 英文 121 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の人工多能性幹細胞 (iPSC) の市場規模は、2023年の34億米ドルから、予測期間中に9.1%のCAGRで推移し、2028年末には52億米ドルの規模に成長すると予測されています。

非統合法の部門は、2023年の21億米ドルから、10.1%のCAGRで推移し、2028年末には34億米ドルに達すると予測されています。また、統合法の部門は、2023年の13億米ドルから、7.5%のCAGRで推移し、2028年末には18億米ドルに達すると予測されています。

当レポートでは、世界の人工多能性幹細胞 (iPSC) の市場を調査し、市場の定義・概要、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

  • 市場の見通し
  • 市場サマリー

第3章 市場概要

  • 多能性因子
  • 研究と治療の意義

第4章 市場力学

  • 市場促進要因
  • iPS細胞のR&Dの拡大
  • バイオテクノロジー産業への投資の増加
  • 慢性疾患の有病率の上昇
  • 精密医療におけるiPSCの使用

第5章 人工多能性幹細胞 (iPSC) の用途

  • 学術研究
  • 薬理毒性スクリーニング
  • 創薬・開発
  • 疾患モデリング
  • ヒト組織工学
  • 細胞治療
  • 新技術

第6章 人工多能性幹細胞 (iPSC) 市場：分類・予測

  • 市場概要
  • 米国
  • 欧州
  • アジア太平洋
  • iPSCの生成
  • 市場概要：用途別
  • iPSC製品市場
  • iPSC由来組織細胞市場
  • 課題
  • iPSCとその派生細胞市場：種別
  • 世界市場
  • iPSC製品の主要サプライヤーおよびメーカー
  • iPSC市場：用途別
  • iPSC市場：製品機能別
  • 世界市場
  • 地域市場
  • iPSC市場：エンドユーザー別

第7章 人工多能性幹細胞 (iPSC) の研究用途市場

  • iPSCの研究製品タイプ
  • 主要企業
  • 主要商業団体
  • 主要非営利団体
  • 市場シェア・予測

第8章 人工多能性幹細胞 (iPSC) 受託サービス市場

  • iPSC契約サービスのタイプ
  • 主要企業
  • 市場シェア・予測

第9章 臨床用途市場動向の分析

  • 臨床試験
  • 加齢性黄斑変性症
  • 虚血性心疾患
  • パーキンソン病
  • 移植片対宿主病（GvHD）
  • 脊髄損傷
  • 角膜修復
  • 癌
  • 推進因子
  • 抑制要因
  • 技術
  • 規則
  • 市場での受容
  • 臨床効率

第10章 競合情勢

  • M&A
  • 戦略的提携

第11章 企業プロファイル

  • ADDGENE
  • ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.
  • ALSTEM
  • APPLIED BIOLOGICAL MATERIALS INC.（ABM）
  • APPLIED STEMCELL INC.
  • ATCC
  • AXOL BIOSCIENCE LTD.
  • BIO-TECHNE CORP.
  • BLUEROCK THERAPEUTICS
  • BRISTOL MYERS SQUIBB（IPIERIAN）
  • CELL SIGNALING TECHNOLOGY（CST）
  • CORNING INC.
  • CREATIVE BIOARRAY
  • FATE THERAPEUTICS
  • FUJIFILM CELLULAR DYNAMICS INC.（FCDI）
  • GENECOPOEIA INC.
  • GENTARGET INC.
  • ID PHARMA CO. LTD.
  • INVIVOGEN
  • LONZA GROUP LTD.
  • MEGAKARYON CORP.
  • MERCK KGAA
  • NCARDIA
  • NEWCELLS BIOTECH
  • PEPROTECH INC.
  • PLASTICELL LTD.
  • PROMEGA CORP.
  • PROMOCELL GMBH
  • QIAGEN NV
  • REPROCELL INC.
  • SCIENCELL RESEARCH LABORATORIES
  • STEMCELL TECHNOLOGIES
  • SYSTEM BIOSCIENCES INC.
  • TAKARA BIO USA INC.（CLONTECH LABORATORIES）
  • THERMO FISHER SCIENTIFIC
  • VERTEX PHARMACEUTICALS INC.
  • WAISMAN BIOMANUFACTURING

第12章 付録：頭字語

図表

List of Tables

  • Summary Table : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
  • Table 1 : Global Market for Induced Pluripotent Stem Cells, by Region, Through 2028
  • Table 2 : U.S. Market for Induced Pluripotent Stem Cells, by State, Through 2028
  • Table 3 : European Market for Induced Pluripotent Stem Cells, by Country, Through 2028
  • Table 4 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Country, Through 2028
  • Table 5 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
  • Table 6 : Global Market for Induced Pluripotent Stem Cells, by Method, Through 2028
  • Table 7 : Global Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 8 : U.S. Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 9 : European Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 10 : Asia-Pacific Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 11 : Rest of the World Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 12 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, Through 2028
  • Table 13 : Global Market for Induced Pluripotent Stem Cell-derived Cells, by Species, Through 2028
  • Table 14 : Major Commercial Suppliers of Induced Pluripotent Stem Cell Products, by Country
  • Table 15 : Major Commercial Manufacturers of Induced Pluripotent Stem Cells, by Country
  • Table 16 : Global Market for Induced Pluripotent Stem Cell-derived Cells, by Application, Through 2028
  • Table 17 : Global Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 18 : U.S. Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 19 : European Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 20 : Asia-Pacific Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 21 : RoW Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 22 : Global Market for Induced Pluripotent Stem Cells, by End Use, Through 2028
  • Table 23 : Global Market for Induced Pluripotent Stem Cell-related Products, by Function, Through 2028
  • Table 24 : Major University and Institute Facilities for Induced Pluripotent Stem Cell Research, by Location/Country
  • Table 25 : Major Companies Providing iPSC Contract Services, by State/Country
  • Table 26 : Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2028
  • Table 27 : Induced Pluripotent Stem Cells Pipeline (Interventional Trials)*
  • Table 28 : Bio-Techne: Annual Financials/Revenue, 2022
  • Table 29 : Bristol Myers Squibb: Financials/Revenue, 2022
  • Table 30 : Corning Inc.: Financials/Revenue, 2022
  • Table 31 : Qiagen NV: Annual Financials/Revenue, 2022
  • Table 32 : Thermo Fisher Scientific: Annual Financials/Revenue, 2022
  • Table 33 : Acronyms Used in the iPSCs Industry

List of Figures

  • Summary Figure : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, 2021-2028
  • Figure 1 : Global Market Share of Induced Pluripotent Stem Cells, by Region, 2022
  • Figure 2 : U.S. Market Share of Induced Pluripotent Stem Cells, by State, 2022
  • Figure 3 : European Market Share of Induced Pluripotent Stem Cells, by Country, 2028
  • Figure 4 : Asia-Pacific Market Share of Induced Pluripotent Stem Cells, by Country, 2022
  • Figure 5 : Global Market Share of Induced Pluripotent Stem Cells, by Reprogramming Method, 2022
  • Figure 6 : Global Market Share of Induced Pluripotent Stem Cells, by Method, 2022
  • Figure 7 : Global Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 8 : U.S. Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 9 : European Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 10 : Asia-Pacific Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 11 : Rest of the World Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 12 : Global Market Share of Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2022
  • Figure 13 : Global Market Share of Induced Pluripotent Stem Cell-derived Cells, by Application, 2022
  • Figure 14 : Global Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 15 : U.S. Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 16 : European Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 17 : Asia-Pacific Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 18 : RoW Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 19 : Global Market Share of Induced Pluripotent Stem Cells, by End Use, 2022
  • Figure 20 : Global Market Share of Induced Pluripotent Stem Cell-related Products, by Function, 2022
  • Figure 21 : Global Market Share of Induced Pluripotent Stem Cell Contract Services, by Region, 2022
  • Figure 22 : Clinical-trial Analysis: Induced Pluripotent Stem Cells
  • Figure 23 : Bio-Techne: Annual Financials/Revenue, 2021 and 2022
  • Figure 24 : Bio-Techne: Revenue Share, by Country/Region, 2022
  • Figure 25 : Bio-Techne: Revenue Share, by Business Segment, 2022
  • Figure 26 : Bristol Myers Squibb: Financials/Revenue, 2021 and 2022
  • Figure 27 : Bristol Myers Squibb: Revenue Share, by Business Unit, 2022
  • Figure 28 : Bristol Myers Squibb: Revenue Share, by Country/Region, 2022
  • Figure 29 : Corning Inc.: Financials/Revenue, 2021 and 2022
  • Figure 30 : Corning Inc.: Revenue Share, by Business Segment, 2022
  • Figure 31 : Qiagen NV: Annual Financials/Revenue, 2021 and 2022
  • Figure 32 : Qiagen NV: Revenue Share, by Business Unit, 2022
  • Figure 33 : Qiagen NV: Revenue Share, by Region, 2022
  • Figure 34 : Thermo Fisher Scientific: Annual Financials/Revenue, 2021 and 2022
  • Figure 35 : Thermo Fisher Scientific: Revenue Share, by Business Unit, 2022
  • Figure 36 : Thermo Fisher Scientific: Revenue Share, by Region, 2022
目次
Product Code: BIO135E

Highlights:

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.

The global market for iPSCs generated by non-integrated method is expected to grow from $2.1 billion in 2023 and forecast to reach $3.4 billion by the end of 2028, at a CAGR of 10.1% from 2023 through 2028.

The global market for iPSCs generated by integrated method is expected to grow from $1.3 billion in 2023 and forecast to reach $1.8 billion by the end of 2028, at a CAGR of 7.5% from 2023 through 2028.

Report Scope:

This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types. Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.

This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.

This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market's growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028. One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.

Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.

The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.

Report Includes:

  • 34 data tables
  • An overview of the global market for induced pluripotent stem cells (iPSCs)
  • Analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by reprogramming method, method, application, derived tissue cell type, species, product function, end use, and geographic region
  • Analysis of the market's dynamics, including drivers, restraints and opportunities, and the regulatory environments impacting the market
  • Assessment of R&D activity in the iPSC segment, as well as new developments and pipeline products
  • Information on the latest research activities, emerging technologies, and clinical trials
  • Market share analysis of the key companies and coverage of mergers & acquisitions, joint ventures, collaborations, and partnerships
  • Profiles of the major players in the industry

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • What's New in This Update?
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary

Chapter 3 Market Overview

  • Introduction
  • Pluripotency Factors
  • Research and Therapeutic Significance

Chapter 4 Market Dynamics

  • Market Drivers
  • Growing Research and Development in iPSCs
  • Increased Investment in Biotechnology Industry
  • Rising Prevalence of Chronic Diseases
  • Use of iPSCs in Precision Medicine

Chapter 5 Induced Pluripotent Stem Cell Applications

  • Academic Research
  • Pharmaco-toxicological Screening
  • Drug Discovery and Development
  • Disease Modeling
  • Tissue Engineering
  • Cell Therapy
  • Emerging Technologies

Chapter 6 Induced Pluripotent Stem Cell Market Segmentation and Forecast

  • Market Overview
  • U.S.
  • Europe
  • Asia-Pacific
  • Generation of Induced Pluripotent Stem Cells
  • Application-based Market Overview
  • Induced Pluripotent Stem Cells Product Market
  • Induced Pluripotent Stem Cell-derived Tissue Cell Market
  • Challenges
  • Induced Pluripotent Stem Cells and Their Derivative Cell Market, by Species
  • Global Market
  • Major Suppliers and Manufacturers of Induced Pluripotent Stem Cell Products
  • Market for Induced Pluripotent Stem Cell-derived Cells, by Application
  • Market for Induced Pluripotent Stem Cells, by Product Function
  • Global Market
  • Regional Markets
  • Market for Induced Pluripotent Stem Cells, by End Use

Chapter 7 Induced Pluripotent Stem Cells Research Application Market

  • Induced Pluripotent Stem Cells Research Product Types
  • Major Players
  • Major Commercial Entities
  • Major Noncommercial Organizations
  • Market Shares and Projections

Chapter 8 Induced Pluripotent Stem Cell Contract Service Market

  • Induced Pluripotent Stem Cell Contract Service Types
  • Major Players
  • Market Shares and Projections

Chapter 9 Clinical Application Market Trend Analysis

  • Clinical Trials
  • Age-related Macular Degeneration
  • Ischemic Heart Disease
  • Parkinson's Disease
  • Graft-versus-host Disease (GvHD)
  • Spinal Cord Injuries
  • Corneal Repair
  • Cancer
  • Driving Forces
  • Limiting Factors
  • Technologies
  • Regulations
  • Market Acceptance
  • Clinical Efficiency

Chapter 10 Competitive Landscape

  • Mergers and Acquisitions
  • Strategic Alliances

Chapter 11 Company Profiles

  • ADDGENE
  • ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.
  • ALSTEM
  • APPLIED BIOLOGICAL MATERIALS INC. (ABM)
  • APPLIED STEMCELL INC.
  • ATCC
  • AXOL BIOSCIENCE LTD.
  • BIO-TECHNE CORP.
  • BLUEROCK THERAPEUTICS
  • BRISTOL MYERS SQUIBB (IPIERIAN)
  • CELL SIGNALING TECHNOLOGY (CST)
  • CORNING INC.
  • CREATIVE BIOARRAY‎
  • FATE THERAPEUTICS
  • FUJIFILM CELLULAR DYNAMICS INC. (FCDI)
  • GENECOPOEIA INC.
  • GENTARGET INC.
  • ID PHARMA CO. LTD.
  • INVIVOGEN
  • LONZA GROUP LTD.
  • MEGAKARYON CORP.
  • MERCK KGAA
  • NCARDIA
  • NEWCELLS BIOTECH
  • PEPROTECH INC.
  • PLASTICELL LTD.
  • PROMEGA CORP.
  • PROMOCELL GMBH
  • QIAGEN NV
  • REPROCELL INC.
  • SCIENCELL RESEARCH LABORATORIES
  • STEMCELL TECHNOLOGIES‎
  • SYSTEM BIOSCIENCES INC.
  • TAKARA BIO USA INC. (CLONTECH LABORATORIES)
  • THERMO FISHER SCIENTIFIC
  • VERTEX PHARMACEUTICALS INC.
  • WAISMAN BIOMANUFACTURING

Chapter 12 Appendix: Acronyms